{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:58:03Z","timestamp":1790683083906,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Genetic counseling and germline genetic testing are essential components of ovarian cancer care; however, their implementation in routine clinical practice remains inconsistent. This study aimed to evaluate the utilization of genetic counseling and testing among patients with ovarian cancer and identify barriers to implementation within routine care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A single-center, retrospective questionnaire-based study was conducted among patients who underwent surgical treatment for ovarian malignancies between January 2021 and June 2025. Patient-reported data on information provision, referral pathways, organizational access, satisfaction, and barriers were linked with clinical and demographic characteristics. Descriptive analyses were performed, reflecting the exploratory nature of the study. A problem frequency (PF) framework, defined as the proportion of responses indicating a problem, was applied to identify and rank patient-reported barriers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 321 identified patients, 61 were deceased prior to study initiation. Among 256 successfully contacted patients, 132 responded (51.6%). Overall, 115\/132 (87.1%) reported receiving information regarding genetic counseling, primarily from hospital-based physicians (106\/132; 80.3%). Among the 132 questionnaire respondents, 96\/132 (72.7%) attended genetic counseling and 93\/132 (70.5%) proceeded to genetic testing; pathogenic variants were identified in 26\/93 tested patients (28.0%). Genetic counseling among respondents increased from 37.5% in 2021 to 94.7% in 2025. The majority of appointments were self-initiated. The most frequently reported barriers were limited information provision, appointment scheduling difficulties, and travel-related barriers, whereas emotional burden at the time of diagnosis was reported less frequently. Uptake was significantly associated with family history of breast and\/or ovarian cancer, higher educational attainment, and parity. Notably, nearly half of the participants who had not attended genetic counseling (17\/36;47.2%) reported reconsidering uptake after completing the questionnaire.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite recommendations for universal genetic counseling in ovarian cancer care, gaps in implementation remain evident in routine clinical practice. Organizational and informational barriers represent prominent obstacles to uptake. Our findings highlight the potential value of standardized referral pathways, proactive information provision, and repeated patient engagement to facilitate access to genetic services.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12905-026-04940-y","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:05:04Z","timestamp":1790679904000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bridging the gap between guidelines and practice: genetic counseling uptake and barriers in patients with ovarian malignancies"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2576-2269","authenticated-orcid":false,"given":"Walid","family":"Shaalan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Dikow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix K. F.","family":"Kommoss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Smetanay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nourhan","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Riedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyra","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Stroisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilie F.","family":"Torkildsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Foteini","family":"Katsikogianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara Meike","family":"Tretschock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Hassdenteufel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Batarseh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riku","family":"Togawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Azzam Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Deutsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Gerhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Hennigs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa Katharina","family":"Nees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schneeweiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Zivanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Riedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"4940_CR1","volume-title":"Krebs in Deutschland f\u00fcr 2019\/2020","author":"Robert Koch-Institut (RKI)","year":"2023","unstructured":"Robert Koch-Institut (RKI). Krebs in Deutschland f\u00fcr 2019\/2020. Berlin: RKI; 2023."},{"key":"4940_CR2","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1097\/IGC.0b013e3182994365","volume":"23","author":"AP Novetsky","year":"2013","unstructured":"Novetsky AP, Smith K, Babb SA, Jeffe DB, Hagemann AR, Thaker PH, et al. Timing of referral for genetic counseling and genetic testing in patients with ovarian, fallopian tube, or primary peritoneal carcinoma. Int J Gynecol Cancer. 2013;23:1016\u201321.","journal-title":"Int J Gynecol Cancer"},{"key":"4940_CR3","first-page":"284","volume":"68","author":"LA Torre","year":"2018","unstructured":"Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68:284\u201396.","journal-title":"CA Cancer J Clin"},{"key":"4940_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13053-018-0095-z","volume":"16","author":"RI Vogel","year":"2018","unstructured":"Vogel RI, Niendorf K, Lee H, Petzel S, Lee HY, Geller MA. A qualitative study of barriers to genetic counseling and potential for mobile technology education among women with ovarian cancer. Hered Cancer Clin Pract. 2018;16:13.","journal-title":"Hered Cancer Clin Pract"},{"key":"4940_CR5","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s12687-019-00427-6","volume":"11","author":"I Van de Beek","year":"2020","unstructured":"Van de Beek I, Smets EMA, Legdeur MA, de Hullu JA, Lok CAR, Buist MR, et al. Genetic counseling of patients with ovarian carcinoma: acceptance, timing, and psychological wellbeing. J Community Genet. 2020;11:183\u201391.","journal-title":"J Community Genet"},{"key":"4940_CR6","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1007\/s10897-013-9598-y","volume":"22","author":"SV Petzel","year":"2013","unstructured":"Petzel SV, Vogel RI, Bensend T, Leininger A, Argenta PA, Geller MA. Genetic risk assessment for women with epithelial ovarian cancer: referral patterns and outcomes in a university gynecologic oncology clinic. J Genet Couns. 2013;22:662\u201373.","journal-title":"J Genet Couns"},{"key":"4940_CR7","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","volume":"30","author":"K Alsop","year":"2012","unstructured":"Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012;30:2654\u201363.","journal-title":"J Clin Oncol"},{"key":"4940_CR8","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ejca.2016.03.009","volume":"61","author":"M Arts-de Jong","year":"2016","unstructured":"Arts-de Jong M, de Bock GH, van Asperen CJ, Mourits MJ, de Hullu JA, Kets CM. Germline BRCA1\/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review. Eur J Cancer. 2016;61:137\u201345.","journal-title":"Eur J Cancer"},{"key":"4940_CR9","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016;375:2154\u201364.","journal-title":"N Engl J Med"},{"key":"4940_CR10","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Krebshilfe D. April, AWMF): S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren, Langeversion 6.1, 2026, AWMF-Registernummer: 032\/035OL. https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/ovarialkarzinom. Accessed 2026."},{"key":"4940_CR11","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s00103-020-03206-8","volume":"63","author":"J Schmidtke","year":"2020","unstructured":"Schmidtke J, Epplen JT, Glaubitz R, Grimm T, Nippert RP, T\u00f6nnies H, et al. Humangenetische Beratung in Deutschland: Entwicklung der Inanspruchnahme. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 2020;63:1161\u20137.","journal-title":"Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz"},{"key":"4940_CR12","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/jgc4.1870","volume":"33","author":"N Herold","year":"2024","unstructured":"Herold N, Bredow K, Ernst C, T\u00fcchler A, Bl\u00fcmcke B, Waha A, et al. Implementing mainstream genetic counseling within the area-wide network of the German Consortium Hereditary Breast and Ovarian Cancer (GC-HBOC): Satisfaction of primary care providers with the provided state-of-the-art training by the Cologne Center. J Genet Couns. 2024;33:206\u201315.","journal-title":"J Genet Couns"},{"key":"4940_CR13","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s10897-012-9553-3","volume":"22","author":"N Dekker","year":"2013","unstructured":"Dekker N, van Dorst EB, van der Luijt RB, van Gijn ME, van Tuil M, Offerhaus JA, et al. Acceptance of genetic counseling and testing in a hospital-based series of patients with gynecological cancer. J Genet Couns. 2013;22:345\u201357.","journal-title":"J Genet Couns"},{"key":"4940_CR14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ejca.2004.10.011","volume":"41","author":"EJ Majdak","year":"2005","unstructured":"Majdak EJ, De Bock GH, Brozek I, Perkowska M, Ochman K, Debniak J, et al. Prevalence and clinical correlations of BRCA1\/BRCA2 unclassified variant carriers among unselected primary ovarian cancer cases - preliminary report. Eur J Cancer. 2005;41:143\u201350.","journal-title":"Eur J Cancer"},{"key":"4940_CR15","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ygyno.2005.10.029","volume":"101","author":"S Malander","year":"2006","unstructured":"Malander S, Rambech E, Kristoffersson U, Halvarsson B, Ridderheim M, Borg A, et al. The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer. Gynecol Oncol. 2006;101:238\u201343.","journal-title":"Gynecol Oncol"},{"key":"4940_CR16","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/humu.10090","volume":"20","author":"H Yazici","year":"2002","unstructured":"Yazici H, Glendon G, Yazici H, Burnie SJ, Saip P, Buyru F, et al. BRCA1 and BRCA2 mutations in Turkish familial and non-familial ovarian cancer patients: a high incidence of mutations in non-familial cases. Hum Mutat. 2002;20:28\u201334.","journal-title":"Hum Mutat"},{"key":"4940_CR17","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1136\/bmj.319.7212.720","volume":"319","author":"PD Cleary","year":"1999","unstructured":"Cleary PD. The increasing importance of patient surveys. Now that sound methods exist, patient surveys can facilitate improvement. BMJ. 1999;319:720\u20131.","journal-title":"BMJ"},{"key":"4940_CR18","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s00520-007-0362-4","volume":"16","author":"UR Kleeberg","year":"2008","unstructured":"Kleeberg UR, Feyer P, G\u00fcnther W, Behrens M. Patient satisfaction in outpatient cancer care: a prospective survey using The PASQOC questionnaire. Support Care Cancer. 2008;16:947\u201354.","journal-title":"Support Care Cancer"},{"key":"4940_CR19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s10897-005-9014-3","volume":"15","author":"R Resta","year":"2006","unstructured":"Resta R, Biesecker BB, Bennett RL, Blum S, Hahn SE, Strecker MN, et al. A new definition of Genetic Counseling: National Society of Genetic Counselors\u2019 Task Force report. J Genet Couns. 2006;15:77\u201383.","journal-title":"J Genet Couns"},{"key":"4940_CR20","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1159\/000516376","volume":"17","author":"K Rhiem","year":"2022","unstructured":"Rhiem K, Auber B, Briest S, Dikow N, Ditsch N, Dragicevic N, et al. Consensus recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer. Breast Care (Basel). 2022;17:199\u2013207.","journal-title":"Breast Care (Basel)"},{"key":"4940_CR21","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.ygyno.2020.01.007","volume":"157","author":"MK Frey","year":"2020","unstructured":"Frey MK, Lee SS, Gerber D, Schwartz ZP, Martineau J, Lutz K, et al. Facilitated referral pathway for genetic testing at the time of ovarian cancer diagnosis: uptake of genetic counseling and testing and impact on patient-reported stress, anxiety and depression. Gynecol Oncol. 2020;157:280\u20136.","journal-title":"Gynecol Oncol"},{"key":"4940_CR22","volume-title":"Education at a Glance 2023: OECD Indicators","author":"Organisation for Economic Co-operation and Development (OECD)","year":"2023","unstructured":"Organisation for Economic Co-operation and Development (OECD). Education at a Glance 2023: OECD Indicators. Paris: OECD Publishing; 2023. https:\/\/www.oecd.org\/en\/publications\/2023\/09\/education-at-a-glance2023_581c9602.html. Accessed April 2026."},{"key":"4940_CR23","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","volume":"34","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2023","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Harter P, Leary A. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:833\u201348.","journal-title":"Ann Oncol"},{"key":"4940_CR24","doi-asserted-by":"publisher","first-page":"512","DOI":"10.6004\/jnccn.2024.0052","volume":"22","author":"J Liu","year":"2024","unstructured":"Liu J, Berchuck A, Backes FJ, Cohen J, Grisham R, Leath CA, et al. NCCN Guidelines\u00ae Insights: Ovarian Cancer\/Fallopian Tube Cancer\/Primary Peritoneal Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024;22:512\u20139.","journal-title":"J Natl Compr Canc Netw"},{"key":"4940_CR25","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s10897-016-0040-0","volume":"26","author":"A Kne","year":"2017","unstructured":"Kne A, Zierhut H, Baldinger S, Swenson KK, Mink P, Veach PM, et al. Why Is Cancer Genetic Counseling Underutilized by Women Identified as at Risk for Hereditary Breast Cancer? Patient Perceptions of Barriers Following a Referral Letter. J Genet Couns. 2017;26:697\u2013715.","journal-title":"J Genet Couns"},{"key":"4940_CR26","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.ygyno.2021.05.011","volume":"162","author":"J Lin","year":"2021","unstructured":"Lin J, Sharaf RN, Saganty R, Ahsan D, Feit J, Khoury A, et al. Achieving universal genetic assessment for women with ovarian cancer: Are we there yet? A systematic review and meta-analysis. Gynecol Oncol. 2021;162:506\u201316.","journal-title":"Gynecol Oncol"},{"key":"4940_CR27","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ygyno.2022.08.011","volume":"167","author":"K Bokkers","year":"2022","unstructured":"Bokkers K, Frederix GWJ, Velthuizen ME, van der Aa M, Gerestein CG, van Dorst EBL, et al. Mainstream germline genetic testing for patients with epithelial ovarian cancer leads to higher testing rates and a reduction in genetics-related healthcare costs from a healthcare payer perspective. Gynecol Oncol. 2022;167:115\u201322.","journal-title":"Gynecol Oncol"},{"key":"4940_CR28","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1136\/ijgc-2023-004307","volume":"33","author":"L Lanjouw","year":"2023","unstructured":"Lanjouw L, Mourits MJE, Bart J, Ter Elst A, Berger LPV, van der Hout AH, et al. BRCA1\/2 testing rates in epithelial ovarian cancer: a focus on the untested patients. Int J Gynecol Cancer. 2023;33:1260\u20139.","journal-title":"Int J Gynecol Cancer"},{"key":"4940_CR29","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ygyno.2023.04.029","volume":"174","author":"VM Witjes","year":"2023","unstructured":"Witjes VM, Ligtenberg MJL, Vos JR, Braspenning JCC, Ausems MGEM, Mourits MJE, et al. The most efficient and effective BRCA1\/2 testing strategy in epithelial ovarian cancer: Tumor-First or Germline-First? Gynecol Oncol. 2023;174:121\u20138.","journal-title":"Gynecol Oncol"},{"key":"4940_CR30","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13012-022-01245-0","volume":"17","author":"LJ Damschroder","year":"2022","unstructured":"Damschroder LJ, Reardon CM, Widerquist MAO, Lowery J. The updated Consolidated Framework for Implementation Research based on user feedback. Implement Sci. 2022;17:75.","journal-title":"Implement Sci"},{"key":"4940_CR31","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fpubh.2019.00064","volume":"7","author":"RE Glasgow","year":"2019","unstructured":"Glasgow RE, Harden SM, Gaglio B, Rabin B, Smith ML, Porter GC. RE-AIM Planning and Evaluation Framework: Adapting to New Science and Practice With a 20-Year Review. Front Public Health. 2019;7:64.","journal-title":"Front Public Health"},{"key":"4940_CR32","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1470-2045(20)30388-0","volume":"21","author":"C Maringe","year":"2020","unstructured":"Maringe C, Spicer J, Morris M, Purushotham A, Nolte E, Sullivan R, et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol. 2020;21:1023\u201334.","journal-title":"Lancet Oncol"},{"key":"4940_CR33","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s43018-020-0074-y","volume":"1","author":"M Richards","year":"2020","unstructured":"Richards M, Anderson M, Carter P, Ebert BL, Mossialos E. The impact of the COVID-19 pandemic on cancer care. Nat Cancer. 2020;1:565\u20137.","journal-title":"Nat Cancer"},{"key":"4940_CR34","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1136\/ijgc-2019-001168","volume":"30","author":"S Alimena","year":"2020","unstructured":"Alimena S, Scarpetti L, Blouch EL, Rodgers L, Shannon K, Del Carmen M, et al. Factors associated with referral and completion of genetic counseling in women with epithelial ovarian cancer. Int J Gynecol Cancer. 2020;30:1397\u2013403.","journal-title":"Int J Gynecol Cancer"},{"key":"4940_CR35","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1200\/EDBK_350292","volume":"42","author":"MK Frey","year":"2022","unstructured":"Frey MK, Finch A, Kulkarni A, Akbari MR, Chapman-Davis E. Genetic Testing for All: Overcoming Disparities in Ovarian Cancer Genetic Testing. Am Soc Clin Oncol Educ Book. 2022;42:471\u201382.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"4940_CR36","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.3390\/cancers16142563","volume":"16","author":"LL White","year":"2024","unstructured":"White LL, Sawyer JK, Zepp JM, Prado YK, Reyes AA, Maiyani M, et al. Genetic Testing Uptake among Ovarian Cancer Survivors in the Genetic Risk Analysis in Ovarian Cancer (GRACE) Study. Cancers (Basel). 2024;16:2563.","journal-title":"Cancers (Basel)"},{"key":"4940_CR37","doi-asserted-by":"publisher","first-page":"e0250379","DOI":"10.1371\/journal.pone.0250379","volume":"16","author":"R O\u2019Shea","year":"2021","unstructured":"O\u2019Shea R, Taylor N, Crook A, Jacobs C, Jung Kang Y, Lewis S, et al. Health system interventions to integrate genetic testing in routine oncology services: A systematic review. PLoS ONE. 2021;16:e0250379.","journal-title":"PLoS ONE"},{"key":"4940_CR38","doi-asserted-by":"publisher","first-page":"e23523","DOI":"10.2196\/23523","volume":"10","author":"M Raspa","year":"2021","unstructured":"Raspa M, Moultrie R, Toth D, Haque SN. Barriers and Facilitators to Genetic Service Delivery Models: Scoping Review. Interact J Med Res. 2021;10:e23523.","journal-title":"Interact J Med Res"},{"key":"4940_CR39","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.3390\/cancers14041059","volume":"14","author":"K Bokkers","year":"2022","unstructured":"Bokkers K, Vlaming M, Engelhardt EG, Zweemer RP, van Oort IM, Kiemeney LALM, et al. The Feasibility of Implementing Mainstream Germline Genetic Testing in Routine Cancer Care-A Systematic Review. Cancers (Basel). 2022;14:1059.","journal-title":"Cancers (Basel)"},{"key":"4940_CR40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s44276-025-00202-w","volume":"4","author":"E P\u00e9rez-Ballestero","year":"2026","unstructured":"P\u00e9rez-Ballestero E, Shire SA, Krajc M, Irmejs A, Foretov\u00e1 L, Frank S, et al. Implementing mainstream germline genetic testing in breast cancer across Europe. BJC Rep. 2026;4:3.","journal-title":"BJC Rep"},{"key":"4940_CR41","doi-asserted-by":"publisher","first-page":"e2222092","DOI":"10.1001\/jamanetworkopen.2022.22092","volume":"5","author":"R Kukafka","year":"2022","unstructured":"Kukafka R, Pan S, Silverman T, Zhang T, Chung WK, Terry MB, et al. Patient and Clinician Decision Support to Increase Genetic Counseling for Hereditary Breast and Ovarian Cancer Syndrome in Primary Care: A Cluster Randomized Clinical Trial. JAMA Netw Open. 2022;5:e2222092.","journal-title":"JAMA Netw Open"},{"key":"4940_CR42","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/1745-6215-12-256","volume":"12","author":"LV van de Poll-Franse","year":"2011","unstructured":"van de Poll-Franse LV, Nicolaije KA, Vos MC, Pijnenborg JM, Boll D, Husson O, et al. The impact of a cancer Survivorship Care Plan on gynecological cancer patient and health care provider reported outcomes (ROGY Care): study protocol for a pragmatic cluster randomized controlled trial. Trials. 2011;12:256.","journal-title":"Trials"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-026-04940-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-026-04940-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-026-04940-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:16:49Z","timestamp":1790680609000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12905-026-04940-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4940"],"URL":"https:\/\/doi.org\/10.1186\/s12905-026-04940-y","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"assertion":[{"value":"7 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the Ethics Committee of Heidelberg University Hospital (IRB Approval Number S-155\/2025; April 22, 2025). A written informed consent was obtained from all participating patients.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"482"}}